US pharma major Eli Lilly on Thursday launched the much-awaited diabetes and obesity management drug Mounjaro in India at one-fifth of US price. Lilly launched the drug in a single dose vial following ...

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight ...

Tirzepatide was evaluated in two robust global clinical development programs. (Image Credits: Pexels) Eli Lilly and Company (India) on Thursday announced the launch of Mounjaro in single-dose vial ...

Eli Sharabi, who survived Hamas captivity and whose family was murdered during the October 7th Massacre, arrived at the United Nations in New York where he will brief the ambassadors of the ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the US-based drug company as India, world's most populous country, is ...

The Google Home app is finally adding the ability to double-tap to quick seek through camera history. This is currently part of the Public Preview program. Update 3/19: Google has rolled this out ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Whether you're preparing for university studies in the United States, enhancing your English skills for career advancement, or simply looking to improve your language proficiency, the ELI provides ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

All right. So, I think we should get started here. For those of you who don't know me, my name is Dave Risinger. I'm responsible for diversified biopharma research at Leerink Partners. It's very ...